New obesity drug XW003 tested in teens – early results show promise

NCT ID NCT07143227

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called XW003 in 48 Chinese teenagers with obesity. The main goal was to check safety and how the body processes the drug, while also tracking weight changes. Participants received either the drug or a placebo injection. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
XW003 injection
What this could lead to
If this drug proves safe and effective in larger trials, it could offer a new weight-loss option for teenagers with obesity.
What could go wrong
This is a very early, small phase 1 study with only 48 participants. The drug may not work in larger groups or could have unexpected side effects. It also only included Chinese adolescents, so results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE ADOLESCENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Qilu Hospital of Shandong University

    Jinan, Shandong, 250012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.